Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

azelis australia pty limited - arsenic present as arsenic acid; chromium present as chromium trioxide; copper present as cupric oxide - aqueous concentrate - arsenic present as arsenic acid mineral-arsenic-acid active 210.0 g/l; chromium present as chromium trioxide mineral-chromium-acid active 300.0 g/l; copper present as cupric oxide mineral-copper active 160.0 g/l - mixed function pesticide - fence - timber | timber - for boat construction | timber - for landscaping | timber - for signage | timber - fresh & salt water - borer | termite - mastotermes spp. | timber decay | woodborer | anobiid | giant northern termite | lyctid | mastotermes darwiniensis

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - arsenic trioxide - leukemia, promyelocytic, acute - antineoplastic agents - arsenic trioxide is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 103/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory acute promyelocytic leukaemia (apl)(previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rar-alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

European Union - English - EMA (European Medicines Agency)

mylan ireland limited - arsenic trioxide - leukemia, promyelocytic, acute - antineoplastic agents - arsenic trioxide mylan is indicated for induction of remission, and consolidation in adult patients with:- newly diagnosed low to intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 103/μl) in combination with all trans retinoic acid (atra)- relapsed/refractory acute promyelocytic leukaemia (apl) (previous treatment should have included a retinoid and chemotherapy)characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic acid receptor alpha (pml/rar alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not beenexamined.

European Union - English - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - arsenic trioxide - leukemia, promyelocytic, acute - antineoplastic agents - arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory apl (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rarα) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - arsenic trioxide, quantity: 10 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.,for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl) in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - arsenic trioxide, quantity: 12 mg - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.,for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl) in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - arsenic trioxide, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression. for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl), in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - arsenic trioxide, quantity: 10 mg - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.,for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl) in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.

Canada - English - Health Canada

teva canada limited - arsenic trioxide - solution - 10mg - arsenic trioxide 10mg - antineoplastic agents

Canada - English - Health Canada

teva canada limited - arsenic trioxide - solution - 12mg - arsenic trioxide 12mg - antineoplastic agents